ABSTRACT:
Mucormycosis is a life threating infection caused by mucorales. The mucormycosis is an opportunistic angina fungal infection that occurs in recent pandemic situation, in that patient who are administered the immunosuppressive drugs or in weekend immune system patients mostly. The Ayurveda plays vital role in mucormycosis with maintaining the diet, regular exercise, also maintaining the personnel hygiene. The amphotericin B is the primary therapy and mostly prescribed drug drugs in fungal infection. The mucormycosis is spread through the burn cut, or through the injury entered into the body. The mucormycosis also known as the black fungus or zygomycosis.
Cite this article:
Bhoknal Mayuri Rajesh. The Medication used in the treatment of Mucormycosis infection. Research Journal of Science and Technology. 2024; 16(4):317-0. doi: 10.52711/2349-2988.2024.00046
Cite(Electronic):
Bhoknal Mayuri Rajesh. The Medication used in the treatment of Mucormycosis infection. Research Journal of Science and Technology. 2024; 16(4):317-0. doi: 10.52711/2349-2988.2024.00046 Available on: https://rjstonline.com/AbstractView.aspx?PID=2024-16-4-8
REFERENCE:
1. Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the Mold. Ann Pharmacother [Internet]. 2016; Sep 19; 50(9): 747–57. Available from: http://journals.sagepub.com/doi/10.1177/1060028016655425
2. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: A review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect [Internet]. 2004 [cited 2021 May 30];10(SUPPL. 1):31–47. Available from: https://pubmed.ncbi.nlm.nih.gov/14748801/
3. Pyrgos V, Shoham S, Walsh TJ. Pulmonary zygomycosis [Internet]. Vol. 29, Seminars in Respiratory and Critical Care Medicine. Semin Respir Crit Care Med; 2008 [cited 2021 May 30]. p. 111–20. Available from: https://pubmed.ncbi.nlm.nih.gov/18365993/
4. Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clinical Infectious Diseases, 2012; 54(suppl_1): S8-15
5. Chakrabarti A., Singh R. Mucormycosis in India: unique features. Mycoses. 2014; 57: 85–90. doi: 10.1111/myc.12243.
6. Song Y, Qiao J, Giovanni G, Liu G, Yang H, Wu J, Chen J. Mucormycosis in renal transplant recipients: review of 174 reported casesexternal icon. BMC Infect Dis. 2017 Apr; 17(1): 283.
7. Abdalla A, Adelmann D, Fahal A, Verbrugh H, Van Belkum A, De Hoog S. Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudanexternal icon. J Clin Microbiol. 2002 Mar; 40(3): 1031–1036.
8. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease external icon. Clin Microbiol Rev 2000; 13:236-301.
9. Vallabhaneni S, Mody RK. Gastrointestinal mucormycosis in neonates: a review external icon. Current Fungal Infect Rep. 2015.
10. Francis JR, Villanueva P, Bryant P, Blyth CC. Mucormycosis in children: review and recommendations for management external icon. J Pediatric Infect Dis Soc. 2018: May 15; 7(2): 159-164.
11. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clinical Infectious Diseases, 2005; 41(5): 634-53.
12. Fu Y, Lee H, Collins M, et al. Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene. FEMS Microbiol Lett. 2004;235(1):169–176.
13. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362(9398):1828–1838.
14. Lackner G, Partida-Martinez LP, Hertweck C. Endofungal bacteria as producers of mycotoxins. Trends Microbiol. 2009;17(12):570–576.
15. Alastruey-Izquierdo A, Castelli MV, Cuesta I, et al. In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect. 2009; 15: 71–76.
16. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis external icon. Clin Infect Dis. 2012; Feb;54 Suppl 1: S23-34.
17. Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis external icon. Future Microbiol. 2013 Sep;8(9):1163-75.
18. Spellberg B, Edwards Jr. J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management external icon. Clin Microbiol Rev. 2005 Jul;18(3):556-69.
19. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human diseaseexternal icon. Clin Microbiol Rev 2000; 13:236-301.
20. https://www.researchgate.net/publication/354599263_International_Journal_of_AAyurved_and_Traditional_Medicine_An_Integrative_Approach_for_management_of_Mucormycosis_along_with_Ayurveda#:~:text=Celine,PMID%3A%2015159002
21. Reshma M. Saokar, R. S. Sarashetti, Veena Kanthi, Madhav Savkar, C. V. Nagthan, International Journal of Recent Trends in Science and Technology, ISSN 2277-2812E-ISSN 2249-8109, Volume 8, Issue 2, 2013 pp 134-13
22. Dabur R, Singh H, Chhillar AK, Ali M, Sharma GL.Antifungal potential of Indian medicinal plants. Fitoterapia.2004 Jun;75(3-4):389-91. doi: 10.1016/j.fitote.2004.01.015.PMID: 1515900
23. Gamaletsou, M.N.; Sipsas, N.V.; Roilides, E.; Walsh, T.J. Rhino-orbital-cerebral mucormycosis. Curr. Infect.Dis. Rep. 2012, 14, 423–434.
24. Greenberg, R.N.; Mullane, K.; van Burik, J.A.; Raad, I.; Abzug, M.J.; Anstead, G.; Herbrecht, R.; Langston, A.;Marr, K.A.; Schiller, G.; et al. Posaconazole assalvatherap for zygomycosis. Antimicrob. Agents Chemother.2006, 50, 126–133.
25. Astellas Pharma US. Prescribing Information for Isavuconazonium Sulfate. Available online: https://www.astellas.us/docs/cresemba.pdf (accessed on 1 July 2018)
26. Trang, T.P.; Hanretty, A.M.; Langelier, C.; Yang, K. Use of isavuconazole in patient with voriconazole induced QTc prolongation. Transpl. Infect. Dis. 2017, 19,e12712.
27. Arendrup, M.C.; Jensen, R.H.; Meletiadis, J. In Vitro activity of isavuconaz comparators against clinical isolates of the Mucorales order. Antimicrob. Agents Chemother. 2015, 59, 7735–7742.
28. Luo, G. Gebremariam T. Lee, H.;Edwards,J.E.Jr.;KovandL.;Ibrahim,A.S.Isavuconazoletheraprotects immunosuppressed mice from mucormycosis. Antimicrob. Agents Chemother. 2014; 58: 2450–2453
29. "Diagnosis and Testing of MucormycosiMucormycosiCDC"www.cdc.govJanuary14,2021.
30. "ICD-11 - ICD-11 for Mortality and Morbidity Statistics". icd.who.int. Retrieved May 25, 202 biopsy lants.
31. Celine C, Sindhu A, Muraleedharn MP. Microbial growth
32. inhibition by aparajitha dhooma choornam. Anc Sci Life.
33. 2007 Jan;26(3):4-8. PMID: 22557234; PMCID:
34. PMC3330879
35. Reshma M. Saokar, R. S. Sarashetti, Veena Kanthi, Madhav
36. Savkar, C. V. Nagthan, International Journal of Recent
37. Trends in Science and Technology, ISSN 2277-2812
38. E-ISSN 2249-8109, Volume 8, Issue 2, 2013 pp 134-137
39. Meena, A.K., Kaur, R., Singh, B., Yadav, A., Singh, U.,
40. Sachan, A., Pal, B., & Rao, M.M. (2010). Review on
41. antifungal activities of Ayurvedic Medicinal Plants.
42. Dabur R, Singh H, Chhillar AK, Ali M, Sharma GL.
43. Antifungal potential of Indian medicinal plants. Fitoterapia.
44. 2004 Jun;75(3-4):389-91. doi: 10.1016/j.fitote.20